Go Pro
LON:GENF

Genflow Biosciences Final Earnings Report

Genflow Biosciences logo
GBX 1.92 0.00 (0.00%)
As of 07/20/2026 10:48 AM Eastern

Genflow Biosciences EPS Results

Actual EPS
-GBX 0.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genflow Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genflow Biosciences Announcement Details

Quarter
Final
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genflow Biosciences Earnings Headlines

SIRT6 gene therapy shows promise in aged dogs - ICYMI
Forget SpaceX… this is the REAL #1 IPO of 2026
While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue growth in recorded history - from $1 billion in early 2025 to a projected $50 billion this year. Google, Amazon, Nvidia, and a fund backed by Peter Thiel have already taken positions. The Wall Street Journal projects $559 million in profit in a single quarter. Legendary investor Alexander Green has identified a backdoor ticker that gives regular investors access before an IPO announcement he expects no later than September 29.tc pixel
Genflow Biosciences PLC Announces Notice of AGM
See More Genflow Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genflow Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genflow Biosciences and other key companies, straight to your email.

About Genflow Biosciences

Genflow Biosciences (LON:GENF) is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

View Genflow Biosciences Profile